Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity
BMO Hosts Second Annual Obesity Summit on the Future of the GLP-1+ Market [Yahoo! Finance]
BMO Hosts Second Annual Obesity Summit on the Future of the GLP-1+ Market [Globe and Mail, The (Toronto, Canada)]
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $51.00 price target on the stock.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock, down previously from $75.00.